Christopher e Hopkins
- Role
- Chief Executive Officer at Glafabra Therapeutics
- Location
- Park City, UT, US
- LinkedIn followers
- 500 followers
About Christopher e Hopkins
Chris is bringing to market a cell-based gene therapy to help patients with Fabry, Pompe…
Experience
Chief Executive Officer
Sep 2024 — Present
At Glafabra Therapeutics we are building durable cell therapies for enzyme deficiency disorders that effect 80M patients worldwide. Our lead asset GT-GLA-S03 is in Fabry disease ant its therapeutic durability is now well documented in publications of Canadian clinical trials. Other diseases targets in metabolic disorders are under development using our STEM, TRAM and iTRAM technologies.
Education
University of Utah
BS, Biology
1986 — 1991
Boston University
Ph. D., Molecular-Cellular Biology and Biochemistry
1997 — 2003
Westminster University
Master of Business Administration (MBA), Project-based degree
2010 — 2012
Skills
- Genetics
- Licensing
- Drug Discovery
- Laboratory
- Drug Development
- Intellectual Property
- Sequencing
- Hplc
- Research
- Genomics
- Technology Transfer
- Lifesciences
- Protein Expression
- Assay Development
- Life Sciences
- Pcr
- Western Blotting
- Pharmaceutical Industry
- Biochemistry
- Nmr
- Molecular Biology
- Patents
- Toxicology
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.